Literature DB >> 12939414

Mild cognitive impairment: directions for future research.

C A Luis1, D A Loewenstein, A Acevedo, W W Barker, R Duara.   

Abstract

Mild cognitive impairment (MCI), an intermediate state between normal aging and dementia, is characterized by acquired cognitive deficits, without significant decline in functional activities of daily living. Studies conducted on MCI have introduced new concepts regarding the possible distinctions between normal and pathologic aging of the brain. Neuroimaging and genetic testing have aided in the identification of individuals at increased risk for dementia. The measurement of change in cognitive and functional status in MCI remains challenging, because it requires instruments that are more sensitive and specific than those considered adequate for research in dementia. The authors provide an overview of the many methods that have been used to study MCI and directions that may help achieve greater uniformity in methodology. Considerable heterogeneity exists in research methodology used to study the epidemiology, thresholds for cognitive and functional impairment, rate of progression, risk factors, and defining subtypes of MCI. This article emphasizes the need for uniformity in the use of 1) appropriate and sensitive neuropsychological and functional measures to diagnose MCI, 2) reliable methods to determine progression or improvement of cognitive impairment, and 3) instruments in epidemiologic studies to establish population estimates for diverse ethnic and cultural groups. Greater consensus is needed to standardize definitions and research methodology for MCI, so as to make future studies more comparable and more useful for designing effective treatment strategies.

Entities:  

Mesh:

Year:  2003        PMID: 12939414     DOI: 10.1212/01.wnl.0000080366.90234.7f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

1.  Functional evaluation distinguishes MCI patients from healthy elderly people--the ADCS/MCI/ADL scale.

Authors:  H Pedrosa; A De Sa; M Guerreiro; J Maroco; M R Simoes; D Galasko; A de Mendonca
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

3.  Complex activities of daily living vary by mild cognitive impairment subtype.

Authors:  Katherine J Bangen; Amy J Jak; Dawn M Schiehser; Lisa Delano-Wood; Elizabeth Tuminello; S Duke Han; Dean C Delis; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2010-04-07       Impact factor: 2.892

4.  Performance-based measures of everyday function in mild cognitive impairment.

Authors:  Terry E Goldberg; Jeremy Koppel; Lynda Keehlisen; Erica Christen; Ute Dreses-Werringloer; Concepcion Conejero-Goldberg; Marc L Gordon; Peter Davies
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

5.  Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis.

Authors:  Barbara Borroni; Daniela Perani; Marcella Broli; Francesca Colciaghi; Valentina Garibotto; Barbara Paghera; Chiara Agosti; Raffaele Giubbini; Monica Di Luca; Alessandro Padovani
Journal:  J Neurol       Date:  2005-06-24       Impact factor: 4.849

6.  Leisure activities and the risk of amnestic mild cognitive impairment in the elderly.

Authors:  J Verghese; A LeValley; C Derby; G Kuslansky; M Katz; C Hall; H Buschke; R B Lipton
Journal:  Neurology       Date:  2006-02-08       Impact factor: 9.910

7.  Plasma homocysteine and risk of mild cognitive impairment.

Authors:  Christiane Reitz; Ming-Xin Tang; Joshua Miller; Ralph Green; José A Luchsinger
Journal:  Dement Geriatr Cogn Disord       Date:  2008-12-16       Impact factor: 2.959

8.  Non-cognitive psychopathological symptoms associated with incident mild cognitive impairment and dementia, Alzheimer's type.

Authors:  Antonio Lobo; Raúl López-Antón; Concepción de-la-Cámara; Miguel Angel Quintanilla; Antonio Campayo; Pedro Saz
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

Review 10.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.